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Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial
Infarction Receiving XIENCE V Everolimus-Eluting Stents: Four-Year Results
from the XIENCE V USA Study
Krishnankutty Sudhir1, Vivian W. Mao1, Sherry Cao2, David Rutledge1
1Abbott Vascular, Santa Clara, CA, 2Abbott Vascular, Santa Clara , CA
Background: XIENCE V USA is a prospective, multicenter, single-arm, FDA con-
dition- of-approval study to evaluate the safety and effectiveness of the XIENCE V
Everolimus Eluting Stent (XIENCE V, Abbott Vascular, Santa Clara, CA) in a real-
world, all-comer population. Clinical outcomes at 1 year in AMI patients have been
previously reported with low rates of target lesion revascularization (TLR), cardiac
death, MI and stent thrombosis (ST). Whether these early results from XIENCE V
USA in AMI are sustained long term has not been reported.
Methods: This study consecutively enrolled 5054 patients undergoing PCI with
XIENCE V only from July to December 2008. A total of 4176 patients who completed
4 year clinical follow up or experienced endpoint events were included in this anal-
ysis. Clinical outcomes in patients with (n¼667, 125 patients with STEMI) and
without (n¼3509) AMI were compared up to 4 years.
Results: Mean age, gender distribution, lesion length, and number of lesions and
vessels treated were similar across the two groups. The AMI group had a fewer di-
abetics, lower rates of dyslipidemia, hypertension, but higher rates of tobacco use,
unstable angina, prior MI, B2/C lesions, compared to the non-AMI group. Clinical
outcomes at 4 years are shown in the table.Table. Clinical outcomes through 4 years
AMI
(N ¼ 667)
(L ¼ 921)
Non-AMI
(N¼3509)
(L ¼ 4918) P-value
Cardiac Death 6.3% 4.9% 0.1585
MI (WHO deﬁnition) 6.9% 4.4% 0.0093
Q-MI 3.5% 1.2% 0.0003
NQMI 3.9% 3.2% 0.3208
Target Lesion Revascularization (TLR) 10.9% 10.4% 0.7189
Target Lesion Failure (TLF) 18.1% 15.3% 0.0897
Early ST (def./prob.) 0-30 days 0.76% 0.37% 0.1893
Late ST (def./prob.) 31-365 days 0.32% 0.51% 0.7555
Very late ST (def./prob.) 1-2 year 0.17% 0.13% 0.5624
Very late ST (def./prob.) 2-3 year 0.37% 0.13% 0.2268
Very late ST (def./prob.) 3-4 year 0.57% 0.20% 0.1402
Overall ST(def./prob.) 0-4 years 2.38% 1.44% 0.1333
TLF: composite of cardiac death, MI attributed to target vessel, and TLRConclusions: In this large, multicenter, real-world study, low clinical event rates at 1
year were sustained through 4 years. Although the rates of clinical outcomes in AMI
patients were slightly higher than those in non-AMI patients, the rates remained low in
both groups. A stent design that combines thin struts, a durable ﬂuoropolymer and
optimal drug dose likely underlies low long term event rates, even in thrombotic lesions.B12 JACC Vol 64/11/Suppl B jTCT-40
10 mg/L of high-sensitivity C-reactive protein on admission is a powerful
predictive marker in patients with ST-segment elevation myocardial infarction,
but not in patients with non-ST-segment elevation myocardial infarction
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Background: C-reactive protein is an important inﬂammatory marker even in acute
phase. Limited date are available whether high-sensitivity C-reactive protein (hs-CRP)
on admission predicts long-term clinical outcome depending on clinical presentation
deﬁned as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment
elevation myocardial infarction (NSTEMI).
Methods:Weenrolled consecutive 3,962 acutemyocardial infarction (AMI) patientswho
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnvergent
REgistry of cAtholic and chonnAm university for AMI) from January 2004 to December
2009.Theprimaryendpointwas a composite of all-causedeath, anymyocardial infarction,
and any revascularization. Cut-off level of initial hs-CRP was 10 mg/L.
Results: Median follow up duration was 38.3 months (interquartile range 22.8 to
55.9months). Elevated hs-CRP was observed in 1,439 patients (36.3%). The rate of
primary endpoint was higher in high hs-CRP group (37.5% vs. 25.8%; 540 events vs.
652 events, P< 0.001). In multivariable Cox proportional hazards regression, high hs-
CRP level is independent predictor of primary endpoint (hazard ratio (HR) 1.20, 95%
conﬁdence interval (CI) 1.06-1.36, P¼0.003). In subgroup analysis, higher hs-CRP
level is associated with long-term clinical outcome in STEMI, but not in NSTEMI
(HR 1.29, 95% CI 1.10-1.52, P¼0.002. vs. HR 1.13, 95% CI 0.94-1.37, P¼0.20;
Interaction P¼0.023).Conclusions: Hs-CRP level on admission over than 10 mg/L is independent predictor
for long-term clinical outcome in patients with STEMI, but not in patients with
NSTEMI.
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CAUSES OF MORTALITY AFTER PERCUTANEOUS CORONARY
INTERVENTION IN A LARGE REGIONAL CARDIAC CENTRE IN
CANADA
Albert W. Chan1, Gerald J. Simkus1, Tina Yang2, Helen Elliott1, Jahangir Charania1,
Johannes Vuurmans1, Roger Philipp1
1Royal Columbian Hospital, New Westminster, BC, 2Cardiac Services of British
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Background: Mortality after percutaneous coronary intervention (PCI) is considered
as a surrogate marker for the quality of care in interventional cardiology. But mortality
after PCI may be related to multiple factors. We examine the frequencies and the
causes of mortality after PCI in the contemporary practice.
Methods: Royal Columbian Hospital is the tertiary regional cardiac centre of Fraser
Health Region in British Columbia that has a population of 1.9 million, and it provides
24/7 primary STEMI revascularization service for the region. Patients’ demographics
and procedural data are prospectively recorded in the provincial catheterization
database, which is linked to the vital statistics. The cause of death was reviewed
independently by 2 interventional cardiologists through chart review, and was clas-
siﬁed into 3 categories: (1) PCI-related, (2) non-PCI-related cardiac death, and (3)
non-cardiac death. Patients who died suddenly or out-of-the-hospital were all pre-
sumed to have PCI-related death due to stent thrombosis, unless proven otherwise.
Results: From 06/2011 to 12/2013, 6,041 PCI procedures were performed, and 1,847
(31%) cases were done during acute STEMI. A total of 154 (2.5%) patients diedSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMwithin 30 days after the PCI procedure, and 114 (74%) events occurred in the setting
of STEMI. Out of all the deaths, pre-procedural cardiogenic shock, cardiac arrest,
CHF, and sustained ventricular tachycardia, were present in 48%, 31%, 29%, and 7%
patients, respectively. Overall, only 42 (27%) patients died from PCI-related events,
and the majority of these were related to deﬁnite (5%) or presumed (15%) subacute
stent thrombosis. The most common cause of mortality was non-PCI-related cardiac
death (73 patients, 47%), with post-STEMI cardiogenic shock (36%) being the most
common etiology. Forty-four patients (28%) died from non-cardiac-related causes,
and anoxic encephalopathy (16%) after cardiac arrest complicating STEMI was the
most common cause in this category.
Conclusions: The majority of the deaths after PCI in a regional cardiac centre were
related to the patients’ presenting illnesses and comorbidities, rather than PCI-related
causes, which would be a better marker of PCI quality.
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Real world comparison of MGuard stent versus bare metal stent for ST elevation
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Background: The MGuard Stent (MGS) was designed to prevent distal emboli-
sation of thrombus and has been shown to improve microcirculation in ST-eleva-
tion myocardial infarction (STEMI). However, there are no real world data
comparing it with the bare metal stent (BMS). The aim of this study is to deter-
mine the efﬁcacy and safety of the MGS in STEMI in the real world compared to
the BMS.
Methods: All STEMI patients undergoing primary angioplasty between July 2011
and January 2013 were included in the study except patients with cardiogenic shock
(Killip IV) or those in which the DES was implanted. In total, 262 patients were
included from a single centre, of which 35.9% had an MGS implanted. Two groups of
79 patients were established after propensity score matching (PSM), and they were
similar in terms of baseline and periprocedural variables.
Results: The mean follow-up was 321  12.94 days. There was no difference in
mortality (7.6% in both groups), major adverse cardiac events (MACE) (20.3% vs.
12.7%, P ¼ 0.198), non-cardiac mortality or non-fatal myocardial infarction (6.3%
in both groups). Target lesion revascularisation (TLR) was signiﬁcantly higher in
the MGS group (11.4% (9) vs. 1.3% (1) P < 0.01; RR 10.02 [1.23 to 81.16])
(Table 1).Table 4
Unmatched Matched
MGS
(n ¼ 92)
BMS
(n ¼ 170) P
MGS
(n ¼ 79)
BMS
(n ¼ 79) P
MACE 18.5% (17) 14.1 (24) 0.512 20.3% (16) 12.7% (10) 0.198
All-cause mortality 6.5% (6) 8.8% (15) 0.354 7.6% (6) 7.6% (6) 1
Cardiovascular
mortality and non-
fatal MI
7.6% (7) 7.1 (12) 0.870 6.3% (5) 6.3% (5) 1
Reinfarction 4.3% (4) 2.4% (4) 0.370 5.1% (4) 2.5% (2) 0.405
Heart failure 3.2% (3) 1.7% (3) 0.290 3.8% (3) 1.3% (1) 0.305
TLR 9.8%(9) 2.9% (5) 0.019 11.4% (9) 1.3% (1) 0.009
TVR 9.8%(9) 2.9% (5) 0.019 11.4% (9) 1.3% (1) 0.009
Stent thrombosis 2.2% (2) 0.6% (1) 0.250 2.4% (2) 1.3% (1) 0.560
Acute 1.1% (1) 0.0% (0) 1.3% (1) 0.0% (0)
Subacute 1.1% (1) 0.6% (1) 1.3% (1) 1.3% (1)
Peak troponin I
(ng/dL)
90.16 
82.11
115.53 
128.88
0.444 91.32 
86.08
95.75 
105.20
0.683Conclusions: Our study is the ﬁrst to compare the MGS with the BMS in STEMI in
the real world, and it also appears to conﬁrm that although the MGS is a safe device in
STEMI that is not associated with increased mortality, it is associated with a higher
long-term TLR rate.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-43
Direct Culprit Vessel Primary PCI to LAD Followed by Contra Lateral
Angiography by Transradial Route in Acute Myocardial Infarction - Direct
Study
T. Ghose1, Kuldeep Arora1, S. Yadav1
1Paras Hospitals, Gurgaon, New Delhi, India
Background: Percutaneous coronary intervention (PCI) of the infarct related arter-
y(IRA) during primary PCI for ST elevation myocardial infarction (STEMI) is
appropriate. Two retrospective analyses suggested that, direct PCI to the IRA without
knowledge of the anatomy of the contra lateral artery is feasible .This approach would
shorten the door to balloon time which is a validated surrogate for mortality in AMI.
We have reported the feasibility of such an approach during transradial primary PCI in
a pilot study (Direct prospective study). In the present clinical study we tested the
hypothesis that in anterior STEMI, direct PCI to left anterior descending (LAD) artery
before right coronary artery angiography is feasible and this would shorten the door to
balloon (d2b) time, even in the hands of operators who have shifted from femoral to
radial approach.
Methods: Anterior wall STEMI was diagnosed by standard criteria. All consecutive
patients of anterior MI admitted between March 2012 to April 2014 were studied
prospectively. Patients with cardiogenic shock were excluded. Patients were pre-
treated with chewable aspirin 150 to 325 mg , ticagrelor 180 mg and atorvastatin 80
mg and shifted to cath lab . Radial access was obtained by anterior wall puncture of
the right radial artery. LMCA was hooked with 6F XB guiding catheter and primary
PCI to LAD was done as per standard protocol. After successful PCI to LAD, the
RCA angiogram was performedwith a 5 F TF catheter . All the intervals were
recorded.
Results: 41 patients of anterior MI were treated. 30 drug eluting stents and 12 bio-
resorbable vascular scaffolds were deployed. The median d2b time was 35+11.8
minutes and the mean d2b time was 36.46+ 14.3min. In two cases SL (2) and (8), the
RCA angiogram required multiple attempts with different catheters. Prior RCA
angiogram would have prolonged the median d2b time by 2.45 minutes (p¼0.05 sec)
and mean d2b time by 4.76 minutes (p¼< 0.05 sec).
Conclusions: From this multicenter study, we conclude that in anterior wall
STEMI, it is feasible to perform PCI to LAD directly without knowing the RCA
anatomy which signiﬁcantly shortens the d2b time. Randomized controlled trial is
warranted.TCT-44
Comparison Of in Hospital Clinical Outcomes In Patients with ST Elevation MI
Transferred for Primary PCI from Non-PCI facility With Those Presenting
Directly to PCI facility
Shishir Mathur1, DEVI N. MATHUR2, Alan Ahlberg2, Francis Kiernan2
1Hartford Hospital, University of Connecticut, Hartford, CT, 2Hartford Hospital,
Hartford, CT
Background: Patients with ST elevation myocardial infarction (STEMI) who are
transferred for primary PCI from a non-PCI facility have longer reperfusion times
which may be associated with poorer clinical outcomes. The aim of this study was to
compare in hospital clinical outcomes among patients presenting directly to a PCI
facility (Non Transfer STEMI group) with those transferred from non-PCI facility for
primary PCI (Transfer STEMI group).
Methods: A retrospective analysis of patients undergoing primary PCI for acute
STEMI from July 2009 to Dec 2013 at a tertiary care PCI hospital was performed.
Patients were identiﬁed as Non Transfer STEMI (n¼501) and Transfer STEMI
(n¼507). Demographic characteristics, risk factors and in hospital clinical outcomes
were compared between the two groups.
Results: The basic demographic proﬁles and cardiovascular risk factors were very
similar between the two groups. The percentage of patients who presented with
cardiogenic shock and/or cardiac arrest in both groups was similar (12.8% vs 14.4%
respectively, p¼0.45). The goal door to balloon time (DTB) was achieved in 85%
of patients in Non-Transfer STEMI (< 90 min) group and 33% of patients in
Transfer STEMI group (< 120 min). 38% of patients in the transfer STEMI group
had DTB time between 120 to 180 minutes. Occurrence of Post PCI cardiogenic
shock, CHF and stroke was similar between the 2 groups. The all cause in hospital
mortality was similar in Non Transfer STEMI vs Transfer STEMI group (5.2% vs
5.3%, p¼0.9)ute Myocardial Infarction B13
